NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Pacira BioSciences, Inc. (NASDAQ:PCRX) on behalf of long-term stockholders following a class action complaint that was filed against Pacira on June 16, 2025 with a Class Period from August 2, 2023 – August 8, 2024. Our investigation concerns whether the board of directors of Pacira have breached their fiduciary duties to the company.
According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court “found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid,” and, thus, eVenus is not infringing on anything. Pacira’s ‘495 patent is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. Analysts have noted that the invalidity of the ‘495 patent calls into question the validity of the Company’s other patents, potentially resulting in more generic entrants into the market and increased litigation expenses moving forward.
Following this news, Pacira’s common stock declined dramatically. From a closing market price of $22.36 per share on August 8, 2024, Pacira’s stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day.
If you are a long-term stockholder of Pacira, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
- UFLY Capital Delivers 6.25% Net Return and 20.05% Annualized IRR in H1 2025, Surpassing S&P 500 and Bitcoin - July 14, 2025
- SBX Cars Selects Blueshift to Power Next-Generation Customer Engagement - July 14, 2025
- New study reveals shift in pediatric obesity treatment following AAP guidelines - July 14, 2025
